Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

MAXONA Pharmaceuticals has submitted an IND application seeking approval from the US FDA for its lead compound, MAX-001, to treat acute pain.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.